Cardiac ischemic complications, prevention

Mechanism of Action A glycoprotein Ilb/IIIa receptor inhibitor that rapidly inhibits platelet aggregation by preventing the binding of fibrinogen to GP Ilb/IIIa receptor sites on platelets. Therapeutic Effect Prevents closure of treated coronary arteries. Prevents acute cardiac ischemic complications. 

Indications Adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications... 

B. Indications and use ReoPro is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention or patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. 

Abeiximab is indicated as an adjunct to pcrcutancnus transluminal coronary angioplasty or atherectomy for the prevention of acute cardiac ischemic complications in patients at high risk for abrupt closure of a irealcd coronary vessel. Abcixiniah appears to decrease the incidence of myocardial infaretion. 

Cardiac index and blood pressure must be sufficient to ensure adequate organ perfusion, as assessed by alert mental status, creatinine clearance sufficient to prevent metabolic azotemic complications, hepatic function adequate to maintain synthetic and excretory functions, a stable heart rate and rhythm, absence of ongoing myocardial ischemia or infarction, skeletal muscle and skin blood flow sufficient to prevent ischemic injury, and normal arterial pH (7.34 to 7.47) with a normal serum lactate concentration. These goals are most often achieved with a cardiac index greater than 2.2 L/min/m2, a mean arterial blood pressure greater than 60 mm Hg, and PAOP of 25 mm Hg or greater. 

Abciximab Prevention ot ischemic cardiac complications during percutaneous coronary interventions short-term prevention ot myocardial infarction Atelimomab Treatment ot sepsis Alemtuzumab Chronic lymphocytic leukemia Apolizumab Chronic lymphocytic leukemia Basiliximab Prevention ot acute renal allograft rejection Clenoliximab Rheumatoid arthritis Daclizumab Prevention ot acute renal allograft rejection Edrecolomab Adjuvant therapy tor cancer after colorectal surgery... 

---